Thursday, November 17, 2022 Daily Archives

eBook: Vaccines — From Disease Prevention to Treatment

For over two years, the biopharmaceutical industry has revolved around rapid development, manufacture, and rollout of vaccines in response to the COVID-19 pandemic. Now as the world reverts to some sense of normality, demand has plummeted for the likes of J&J’s viral vector vaccine and Moderna’s messenger RNA (mRNA) vaccine, resulting in the lowering of financial forecasts, ending of manufacturing contracts, and freeing of production capacity. But where do vaccines — the great pharmaceutical success story of the past few…

Ensuring Leak-Free Performance During Tissue Container Shipping Utilizing ASTM D4991

This webcast features: Eric Isberg, Vice President, Life Sciences, Savillex. Companies in the fields of tissue engineering and cell therapy find that when standard, off-the-shelf labware containers are used to transport therapies, the container seal can fail during shipment. For a live tissue or cell sample being shipped to a hospital or clinic as part of a treatment, this can be a catastrophic failure that can lead to damaged samples, surgical delays, and poor patient outcomes. When selecting containers for…

Ireland’s in the (up/down) stream: NIBRT talks bioproduction

The latest edition of the BioProcess Insider Expression Platform has NIBRT’s Killian O’Driscoll speaking on Ireland’s robust biomanufacturing environment, training programs, and vendor-led technologies. Ireland has long established itself as a drug manufacturing hub and is home to commercial production sites run by Big Pharma firms including Pfizer, J&J, Eli Lilly, and AstraZeneca, as well as numerous third-party manufacturing organizations and bioprocess vendor firms. The country has evolved to mirror industry’s shift from small molecule to large molecule, and now…

MilliporeSigma invests $300m to expand biosafety capacity in Maryland

MilliporeSigma says global demand has driven its decision to increase biosafety testing capacity at its Rockville, Maryland facility. MilliporeSigma – the life sciences division of Germany’s Merck KGaA – has invested more than €290 million ($300 million) at its Rockville site, which it claims is the largest biosafety testing investment in the company’s history. The contract development manufacturing organization (CDMO) says the decision to expand is in response to the global demand for these services increasing at a double-digit rate. “Biosafety testing…